Phytochemical basis and antitumor mechanisms of Psoralea corylifolia L.: implications for tumor immunomodulation and therapeutic development

Background

Psoralea corylifolia L. (PCL), a medicinal plant used in Traditional Chinese Medicine for the treatment of "Kidney-Yang deficiency" has long been applied within a multi-component therapeutic framework. This integrative approach aligns with emerging oncological paradigms that emphasize network-based pharmacology; however, a comprehensive correlation between its phytochemical composition and anti-tumor activity remains insufficiently defined.